Evogene (NASDAQ:EVGN – Get Free Report) issued its quarterly earnings data on Tuesday. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.14, Zacks reports. Evogene had a negative return on equity of 158.82% and a negative net margin of 638.12%.
Evogene Stock Performance
Shares of EVGN opened at $0.56 on Tuesday. The firm has a market cap of $4.88 million, a PE ratio of -0.40 and a beta of 1.40. Evogene has a 52-week low of $0.37 and a 52-week high of $1.50. The business’s 50 day moving average price is $0.53 and its two-hundred day moving average price is $0.72.
Analyst Ratings Changes
Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Evogene in a research report on Wednesday, July 8th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Evogene currently has a consensus rating of “Sell”.
Insider Buying and Selling at Evogene
In related news, Director Leon Recanati bought 460,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 11th. The shares were bought at an average price of $0.64 per share, for a total transaction of $294,400.00. Following the transaction, the director directly owned 1,343,886 shares of the company’s stock, valued at approximately $860,087.04. The trade was a 52.04% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 7.40% of the stock is owned by corporate insiders.
Institutional Investors Weigh In On Evogene
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Jane Street Group LLC boosted its position in shares of Evogene by 58.0% during the 1st quarter. Jane Street Group LLC now owns 33,732 shares of the biotechnology company’s stock worth $42,000 after purchasing an additional 12,387 shares in the last quarter. Citadel Advisors LLC grew its stake in Evogene by 169.4% in the third quarter. Citadel Advisors LLC now owns 57,575 shares of the biotechnology company’s stock valued at $66,000 after acquiring an additional 36,206 shares during the period. Finally, XTX Topco Ltd bought a new stake in shares of Evogene during the fourth quarter valued at approximately $25,000. 10.40% of the stock is owned by institutional investors.
About Evogene
Evogene Ltd. is a biotechnology company specializing in the use of computational and predictive biology technologies to design and develop novel products for agriculture and human health. Founded in 2002 and headquartered in Rehovot, Israel, the company has built a proprietary computational platform that integrates genomics, machine learning and data analytics to identify gene targets and biological traits. Evogene’s platform serves as the backbone for its research and development efforts, enabling the discovery of enhanced crop traits, microbial solutions and microbiome-based diagnostics and therapeutics.
In the agricultural sector, Evogene applies its platform to improve crop performance across a range of parameters, including yield enhancement, stress tolerance and resistance to pests and pathogens.
Featured Articles
- Five stocks we like better than Evogene
- Moonshot to Money: Intuitive Machines Lands $600M Defense Win
- Commodities Are Booming, But These 3 ETFs Tell Different Stories
- 3 Active ETFs Making Big Moves in August
- This ETF Is Outperforming by Avoiding the S&P 500’s Biggest Problem
Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.
